Portal de investigación
- Inicio
- Publicaciones
- Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Martin, A. Gonzalez
- Perez, M. J. Rubio
- Heitz, F.
- Christensen, R. D.
- Colombo, N.
- Van Gorp, T.
- Oaknin, A.
- Leary, A.
- Garcia, L. Gaba
- Lebreton, C.
- Gonzalez, L. M. De Sande
- Marin, M. Romeo
- Redondo, A.
- Ginesta, M. P. Barretina
- Fidalgo, J. A. Perez
- Bermejo-Perez, M. J.
- Bruchim, I.
- Ray-Coquard, I. L.
- Selle, F.
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0923-7534, 1569-8041
- Tipo:
- Meeting Abstract
- Páginas:
- 1278-1279
- Factor de Impacto:
- 8,590 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
ANNALS OF ONCOLOGY ELSEVIER
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Martin,AG,Perez,MJR,Heitz,F,Christensen,RD,Colombo,N,Van,T,Oaknin,A et al. Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial. Congress of the European-Society-for-Medical-Oncology (ESMO). 2023. Madrid. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2023 p.p. 1278-1279.